Previous 10 | Next 10 |
Syneos Health press release ( NASDAQ: SYNH ): Q3 Non-GAAP EPS of $1.23 misses by $0.09 . Revenue of $1.34B (-0.7% Y/Y) misses by $40M . Adjusted EBITDA of $210.0M increased 3.7% Y/Y. The company’s Net Leverage Ratio was 3.2x based on trailing twelve ...
Revenue for the third quarter of $1,336.2 million decreased 0.9% on a reported basis and increased 2.2% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $182.2 million ...
Syneos Health ( NASDAQ: SYNH ) is scheduled to announce Q3 earnings results on Friday, November 4th, before market open. The consensus EPS Estimate is $1.32 (+8.2% Y/Y) and the consensus Revenue Estimate is $1.38B (+2.2% Y/Y). Over the last 2 years, SYNH has beaten E...
Summary The market is greatly overestimating the effect of higher rates and inflation on durable goods, materials and financial companies, while underestimating the impact on speculative assets. Rather than driven by positive growth catalysts, the reversal in value leadership duri...
Summary Having suffered through a sharp decline in earnings multiples, small cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings ...
Summary The market is greatly overestimating the effect of higher rates and inflation on durable goods, materials and financial companies, while underestimating the impact on speculative assets. The Strategy underperformed its Russell 2000 benchmark, as positive contributions from...
Summary Equity markets continued their downward slide during the quarter, as investors grew increasingly anxious over aggressive interest rate increases and the growing likelihood of a recession. The Strategy underperformed its benchmark, as positive contributions in industrials a...
Summary Equities continued their slide during the third quarter, as investors grew increasingly anxious over the combination of aggressive interest rate increases and a growing likelihood of recession. Health care proved an impediment to relative performance, as the evaporation of...
MORRISVILLE, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it is introducing a dedicated HUB Patient Suite combining the Company’s advisory, analytics and digitally-e...
MORRISVILLE, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4, 2022, prior to its earnings call at 8:00 a.m. ET. ...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...